Source: Market Exclusive

Zosano Pharma: ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Entry into a Material Definitive Agreement

ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Entry into a Material Definitive Agreement Item 1.01.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating

83/100

Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more